Medical/Pharmaceuticals

HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices

The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies. BOSTON and SUZHOU, China, June 10, 2026 /PRNewswire/ -- HkeyBio, a specialized preclinical CRO focused...

2026-06-10 21:16 6448

QingSong Health Corp (2661.HK) and Basel Medical Sign Strategic Cooperation Memorandum to Explore AI Healthcare Services in Southeast Asia

BEIJING, June 10, 2026 /PRNewswire/ -- Recently, QingSong Health Corp (2661.HK) andBasel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties intend to explore cooperation in AI-enabled healthcare services, insurance-related healthcare solutions, and c...

2026-06-10 21:05 7067

Vatech Completes Full-Portfolio EU MDR Certification

Certification covers all three dental imaging categories and every 2026 model launch HWASEONG, South Korea, June 10, 2026 /PRNewswire/ -- Vatech (KOSDAQ: 043150), a global leader in dental imaging, today announced the completion of EU Medical Device Regulation (MDR; Regulation (EU) 2017/745) cer...

2026-06-10 21:00 4230

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy Key Points * Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic e...

2026-06-10 17:00 4937

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...

2026-06-10 12:06 5073

PromptBio Launched All-New Agentic AI Platform For Life Sciences, Turning Scientific Intent Into Executable Experiments

The PromptBio Platform combines conversational AI with multi-agent orchestration to accelerate discovery from hypotheses to insights PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- PromptBio, a California-based leader in AI for life sciences, announced the launch of the All-New PromptBio Platfo...

2026-06-09 22:07 7156

First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody

* COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease * HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026 * HBM9378/WIN378 has th...

2026-06-09 20:23 5010

SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development

* SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention * SK bioscience is jointly investing with the RIGHT Foundation to drive process development that enhances both efficacy and productivity * "We are committed to improving public health through...

2026-06-09 20:00 3218

Zylox-Tonbridge Recognized as Most Honored Company in Extel 2026 Asia Executive Team Survey

HANGZHOU, China, June 8, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190; "Zylox-Tonbridge" or the "Company"), a Hong Kong-listed medical technology company focused on neurovascular and peripheral vascular interventional products and solutions, announced that it has ...

2026-06-08 18:19 4114

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-06-08 16:30 6710

WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards

DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Scie...

2026-06-08 16:09 3944

OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma

SHANGHAI, June 7, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") ,announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confir...

2026-06-08 08:08 4033

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound. NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Ractigen Therapeutics, a ...

2026-06-06 08:30 6210

SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver

Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281 VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech), a global leader in biotechnology solutions, today announced the launch of SYNMUE™, a clinically validated probiotic featuringLactipl...

2026-06-06 03:15 8774

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, mor...

2026-06-05 22:00 11027

Aphranel® Marks First Anniversary with EU MDR Certification, Arc™ Launch, and Over 150,000 Syringes Delivered

SHANGHAI, June 5, 2026 /PRNewswire/ -- On May 20, 2026, Aphranel® celebrated its first anniversary at the Waldorf Astoria Shanghai on the Bund, marking a major milestone in the brand's international presence in regenerative aesthetics.   Highlights from the Aphranel® First Anniversary Summit in...

2026-06-05 13:20 3986

Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Adminis...

2026-06-05 11:30 4861

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facil...

2026-06-05 10:45 9521

Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day

* WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. * The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate ...

2026-06-04 20:30 4520

PharmaBlock's First Peptide GMP Pilot-scale Plant at PharmaBlock Zhejiang Site Now Operational

Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development NANJING, China, June 4, 2026 /PRNewswire/ -- PharmaBlock Sciences (Stock Code: 300725.SZ) today announced the commissioning of its first peptide pilot-scale GMP p...

2026-06-04 20:21 4169
1 ... 567891011 ... 261

Week's Top Stories